(Total Views: 551)
Posted On: 09/30/2025 7:14:09 AM
Post# of 157632
Great. This means Merck's Keytruda and Bristol Meyers' Opdivo can't be used in esophageal cancers.... unless...
Yes, how can we get immunotherapies to be effective in cancers that have low PD-L1 expression? How in the world could we raise PD-L1 expression in solid-tumor cancers?
Psst. Hey, Merck. Hey, BMS. Got a minute?
Quote:
Changes to both drug labels come amid growing evidence that patients with low or no PD-L1 expression derive limited benefit from these agents...
“I really hope we can see how this evolves and how we can get immunotherapies to be effective in this PD-L1-negative population,” said ODAC member Hanna K. Sanoff, MD, MPH, during the September ODAC meeting. “Until we do that, I just did not see enough evidence that we’re helping people and not harming them.”
Yes, how can we get immunotherapies to be effective in cancers that have low PD-L1 expression? How in the world could we raise PD-L1 expression in solid-tumor cancers?
Psst. Hey, Merck. Hey, BMS. Got a minute?
(20)
(0)
